相关实验视频
Updated: Feb 25, 2026
08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
10.4K
"和你,野兽吗?"他问道. - 一个Ixazomib诱导的与癌症治疗有关的心脏功能障碍病例
Yusuke Hirao1, Kensuke Matsumoto1, Yu Mizutani1
1Department of Internal Medicine, Hyogo Prefectural Tamba Medical Center, Japan.
Internal medicine (Tokyo, Japan)
|February 23, 2026
概括
本病例报告详细介绍了一名81岁的老人,由于多发性骨髓瘤的ixazomib治疗,他患上了与癌症治疗相关的不可逆转的心脏功能障碍 (CTRCD). 他的左心室喷射率 (LVEF) 显著下降,突出显示了一种罕见但严重的副作用.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性骨髓瘤是一种血液性恶性瘤.
- 癌症治疗相关心脏功能障碍 (CTRCD) 是癌症治疗的已知并发症.
- 伊克萨佐米布是一种蛋白酶体抑制剂,用于治疗多发性骨髓瘤.
研究的目的:
- 报告一种罕见的伊克萨佐米布诱导的与癌症治疗相关的不可逆转心脏功能障碍 (CTRCD) 病例.
- 要突出与ixazomib治疗相关的左心室射出分数 (LVEF) 显著下降的潜力.
主要方法:
- 一个81岁的男性患有多发性骨髓瘤的病例报告.
- 不补偿性心力衰竭 (HF) 的临床表现.
- 心声学和多式成像,以评估心脏功能,并排除其他原因.
主要成果:
- 患者在13个月的ixazomib治疗后,LVEF从基线显著下降到35%.
- 由于时间关系和成像发现,人们强烈怀疑伊克萨佐米布诱导的CTRCD.
- 尽管停用了ixazomib并接受了指导方针导向的医疗治疗,但LVEF并没有恢复.
结论:
- 伊克萨佐米布可以诱导不可逆转的CTRCD,这是一个罕见但严重的不良事件.
- 在接受ixazomib的患者中,密切的心脏监测至关重要,特别是那些具有先前存在心血管风险因素的患者.
- 这一案例强调了在瘤病患者中识别和管理CTRCD的重要性.
相关概念视频
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
632
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
632
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
555
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
555
01:26Heart Failure Drugs: Inotropic Agents
1.6K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.6K
01:29Cardiomyopathy VI: Nursing Management
386
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
386
01:14Myocarditis III: Medical Management
251
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
251
01:30Cardiomyopathy II: Dilated Cardiomyopathy
649
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
649